Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (701)	2/18/1998 8:42:00 PM
From: adam hefian	Respond to of 1826

Has anyone called MOGN Inv.Rels. to find out when they plan to make the announcement of Phase2 for MGI 114?

To: seminole who wrote (701)	2/18/1998 11:13:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1826

Richard, Here's some evidence of just how tough the MV522 lung carcinoma line is: Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Kelner MJ, McMorris TC, Estes L, Starr R, Samson K, Varki N, Taetle R Department of Pathology, UCSD Medical Center 92103-8320, USA. The human lung carcinoma cell line MV522 was previously noted to produce extensive metastasis to the lungs, spleen and lymph nodes after subcutaneous transplantation into athymic nude mice. Animals eventually succumb to these metastases, and not primary tumor growth. The ability to produce extensive metastasis after a simple subcutaneous injection in 100% of animals (> 100 tested to date) would be an advantage when screening compounds for anticancer activity. To validate the utility of this xenograft model for testing anticancer agents, we tested the ability of 10 anticancer drugs to either inhibit primary tumor growth and/or prolong life span of MV522-bearing animals. Among the 10 antitumor conventional agents, only mitomycin C and taxol demonstrated primary tumor growth inhibition. Mitomycin C produced a mild increase in median life span of 41% to 63%, while taxol had inconsistent effects. The metastatic MV522 carcinoma model appears to reflect clinical resistance of primary non-small cell lung cancer to conventional chemotherapeutic agents and should be useful for testing new anti-cancer drugs. _______ I guess one issue is how well MGI-114 works in non-mdr tumors. It's conceivable that it works better (or at least very differently) in the mdr-tumors than in non-mdr-tumors. If so, how do you design Phase II's to pick this up? Do you do some (or all) trials in people who've already failed chemo? Advancing it initially as a "last-resort" drug might actually be the quickest route to approval. If it turns out that it needs to be used in combination with something else for good effectiveness, this would complicate the trials process considerably. Peter